(Q38853812)

7 September 2017

1 reference

title

Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors (English)

1 reference

7 September 2017

Michael J Scalese

1

1 reference

7 September 2017

Travis S Reinaker

series ordinal

2

1 reference

7 September 2017

publication date

1 June 2016

1 reference

American Journal of Health-System Pharmacy

7 September 2017

published in

1 reference

7 September 2017

volume

73

1 reference

7 September 2017

issue

12

1 reference

7 September 2017

page(s)

873-879

1 reference

Vasopeptidase inhibition and angio-oedema

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

31 March 2020

Diagnosing angioedema.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Management of angiotensin-converting enzyme inhibitor-induced angioedema.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Ten-year study of causes of moderate to severe angioedema seen by an inpatient allergy/immunology consult service

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Incidence and characteristics of angioedema associated with enalapril

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Nonallergic angioedema: role of bradykinin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Angiotensin-converting enzyme inhibitor-induced angioedema

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Fresh-frozen plasma as a treatment for life-threatening ACE-inhibitor angioedema

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Angiotensin-converting enzyme inhibitor angioedema

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Fresh frozen plasma for progressive and refractory angiotensin-converting enzyme inhibitor-induced angioedema

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Plasma bradykinin in angio-oedema.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Treatment of acquired angioedema with icatibant: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Treatment of ACEI-related angioedema with icatibant: a case series.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

A randomized trial of icatibant in ACE-inhibitor-induced angioedema

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Current role of neprilysin inhibitors in hypertension and heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150482

31 March 2020

Identifiers

DOI

10.2146/AJHP150482

1 reference

7 September 2017

1 reference